Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Recombinant human IgG1 kappa light chain monoclonal antibody targeting plasma kallikrein

EU orphan designation number: EU/3/15/1551   
Active ingredient: Recombinant human IgG1 kappa light chain monoclonal antibody targeting plasma kallikrein
Indication: Treatment of hereditary angioedema
Sponsor: Dyax Ltd
c/o Arnold & Porter UK LLP, Tower 42, Level 30, 25 Old Broad Street, London EC2N 1HQ, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page
Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
13/10/2015 Orphan designation EMA/OD/075/15 (2015)7022 of 09/10/2015
16/12/2015 Corrigendum (2015)9522 of 14/12/2015